The association between three HLA SNPs and MS clinical course†
| MS | Relapse | ΔEDSS | |||||
|---|---|---|---|---|---|---|---|
| SNP | HLA allele or SNP | Number of MS (%) | HR (95% CI) | Number of relapse (%) | HR (95% CI) | Number of 5-year disability measures (%) | β (95% CI) |
| rs9266773‡ | B*44:02 | ||||||
| AA | 60 (88.24) | 1.00 (Reference) | 142 (94.04) | 1.00 (Reference) | 110 (88.00) | −0.86 (−0.93 to −0.80) | |
| AG | 8 (11.76) | 0.44 (0.20 to 0.97) | 9 (5.96) | 0.37 (0.19 to 0.71) | 15 (12.00) | −0.04 (−0.19 to 0.10) | |
| Trend | p=0.043 | p=0.003 | p=0.620 | ||||
| rs9277561‡ | rs9277565[T] | ||||||
| AA | 43 (64.18) | 1.00 (Reference) | 78 (52.35) | 1.00 (Reference) | 76 (61.79) | −0.89 (−0.96 to −0.82) | |
| AG+GG | 24 (35.82) | 1.08 (0.64 to 1.84) | 71 (47.65) | 1.59 (1.04 to 2.43) | 47 (38.21) | +0.04 (−0.10 to 0.18) | |
| Trend | p=0.77 | p=0.033 | p=0.540 | ||||
| rs3135391§ | DRB1*15:01 | ||||||
| GG | 25 (36.76) | 1.00 (Reference) | 50 (33.11) | 1.00 (Reference) | 54 (43.20) | −0.80 (−0.94 to −0.65) | |
| GA+AA | 43 (63.24) | 1.63 (0.97 to 2.73) | 101 (66.89) | 1. 30 (0.82 to 2.06) | 71 (56.80) | −0.11 (−0.27 to 0.05) | |
| Trend | p=0.067 | p=0.260 | p=0.120 | ||||
Disability results presented as geometric mean ΔEDSS (95% CI) for the reference group, while coefficients relative to reference (β (95% CI)) are presented for subsequent levels.
Results in boldface denote significant results (p<0.05).
†Adjusted for age, sex and study recruitment, before adjustment for multiple comparisons.
‡No persons had the GG genotype.
§The homozygous genotypes were combined with the heterozygous ones due to small numbers.
ΔEDSS, annualised disability progression from FDE to 5-year review; EDSS, Expanded Disability Status Scale; FDE, first demyelinating event; MS, clinically definite multiple sclerosis; SNPs, single nucleotide polymorphisms.